NDRG1 and neoplasm: The obvious next step is biomarker-guided trials that stratify by pathway activity—e.g., GLORI/m6A-SAC-seq–derived HR or ferroptosis signatures; NSUN6–m5C–NDRG1 readouts in cervical cancer; or reader-expression in tumor myeloid/DC compartments—to match patients to specific epitranscriptomic levers (138, 144).